Richard L. Wang PhD, MBA

Richard L. Wang Named Chief Executive Officer of Fosun Kite Biotechnology Co., Ltd., a Joint Venture to Lead Development of Axicabtagene Ciloleucel and Other Engineered TCell Therapies for Treatment of Cancers in China. Dr. Wang has extensive experience in the biopharmaceutical industry including US and China based leadership roles at Procter & Gamble, Bristol-Myers Squibb, AstraZeneca and GlaxoSmithKline. He most recently served as Chief Operating Officer of Cellular Biomedicine Group, a U.S. listed clinical-stage immuno-oncology and cell therapy company with operations in China.

Previously, Dr. Wang was Senior Site Leader and Head of Operations for GlaxoSmithKline research and development in Shanghai. He obtained a B.S. degree in Cell Biology from the University of Science & Technology of China, a Ph.D. degree in Molecular Biology from the University of Maryland, Baltimore, and a M.B.A. degree from Xavier University in Cincinnati. Under Dr. Wang's leadership, the joint venture will establish business operations in Shanghai and build a senior leadership team to oversee technical operations and clinical development activities.